EPEmily D Pollock

Emily D Pollock

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emily D Pollock has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Estimation of Antimicrobial-Resistant Mycoplasma genitalium Infections in People Aged 14–59 Years: Results From the National Health and Nutrition Examination Survey, United States, 2017–2018

    by Lisa E Manhart, Mary Bridget Waters, Christine M Khosropour, Kristen M Kreisel, Anika Parker, Emily D Pollock, Kevin Hybiske, Jørgen S Jensen

    Mycoplasma genitalium antimicrobial resistance is common in US sexual health clinics. Population-level prevalence is unknown. We tested National Health and Nutrition Examination Survey (2017–2018) specimens for M genitalium resistance mutations (n = 58). Macrolide resistance prevalence was 42.7% (95% CI, 24.4%–62.7%). Quinolone resistance was not detected. Macrolide resistance testing should guide azithromycin treatment.

  • Open Access

    Modeling the impact of vaccine dose prioritization strategies during the 2022 mpox outbreak

    by Patrick A Clay, Emily D Pollock, Enrique M Saldarriaga, Preeti Pathela, Michelle Macaraig, Jane R Zucker, Bindy Crouch, Ian Kracalik, Ian H Spicknall

    Early in the 2022 mpox outbreak, the US recommendation was to administer two doses of the JYNNEOS vaccine 4 weeks apart. However, because of limited vaccine supply, New York City (NYC) prioritized single dose vaccination. We estimated mpox cases averted by this strategy compared to strategies that prioritized 2-dose vaccination for a smaller portion of the population. We fit a network transmission model to incident mpox cases in NYC. Model output consisted of predicted cases over time when vaccine doses were administered with the “first-dose priority” strategy, compared with counterfactual simulations, where doses were administered to those eligible for a second dose ahead of those waiting for a first dose (“intermediate” strategy), or where individuals were preallocated full courses of the vaccine (“second-dose priority” strategy). We estimate that NYC’s strategy averted 66% (IQR, 47%-78%) of potential mpox cases compared to no vaccination. This “first-dose priority” strategy averted 0.6% (IQR, −11% to 9.8%) more cases than the “intermediate” strategy, and 17% (IQR, 2.9%-38%) more cases than the “second-dose priority” strategy. Thus, for the 2022 mpox outbreak in NYC, preallocating vaccine doses to ensure full vaccination in a high-priority subset of the population would have increased the size of the outbreak.